



RAPID BRAF CODON 600 VARIANT ANALYSIS

Patient Details		Source Information		Sample Information	
Lab Number:	MP19- XXXX	Requester Ref:		Date Received:	02/01/2019
Surname:	Atient	Surgical No.:	18HT 123 A1	Primary Tumour Site:	Skin
Forename:	Penelope	Sample Type:	FFPE Block	Tumour Subtype:	Melanoma
D.O.B. (D/M/Y)	23/06/1946	Consultant:	Smith	Tissue Sample Site:	Skin
Gender:	Female	Hospital:	Hospital	(Whole):	51-75%
				% Tumour (Selected):	

Results

Detected DNA Change: c.1799T>A or c.1799_1800delinsAA or c.1799_1800delinsAT or c.1799_1800delinsAC

Detected Protein Change: p.(Val600Glu) or p.(Val600Asp)

Comment:

There is evidence of BRAF codon 600 mutation in this sample. In melanoma patients, this has been associated with an increased likelihood of response to BRAF-targeted therapy.

Approved by:

Signature:

Name: Dr F. Irst

Date: 02/01/2019

Job Title:

Clinical Scientist

Consultant Histopathologist ✓

BMS (senior)

Checked by:

Signature:

Name: Dr S. Econd

Date: 02/01/2019

Job Title:

BMS

Trainee Clinical Scientist / BMS

Molecular Biology, PhD ✓

This assay was performed on a Biocartis Idylla system using the "BRAF Mutation Test" kit. This assay is CE-IVD certified for use on Melanoma samples with >50% tumour content, with an analytical sensitivity of approximately 1% variant frequency in FFPE samples. It can detect the following mutations; p.Val600Glu (c.1799T>A or c.1799_1800delinsAA), p.Val600Asp (c.1799_1800delinsAT or c.1799_1800delinsAC), p.Val600Lys (c.1798_1799delinsAA), p.Val600Arg (c.1798_1799delinsAG), and p.Val600Met (c.1798G>A). All DNA and Protein changes are given with respect to BRAF reference sequence NM_004333.4.